p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines

Cancer Chemother Pharmacol. 2016 Feb;77(2):349-56. doi: 10.1007/s00280-015-2944-z. Epub 2015 Dec 23.

Abstract

Purpose: Multidrug resistance (MDR) is a major obstacle to the successful treatment of osteosarcoma with chemotherapy. Effectiveness of cancer therapy correlates with the ability to induce a p53-dependent apoptotic response. p53 is a tumor suppressor gene that is mutated in 22 % of osteosarcomas. While impaired p53 has been implicated in the oncogenesis of osteosarcoma, it is unclear whether overexpression of wild-type p53 can increase chemosensitivity in MDR osteosarcoma cells.

Methods: We transfected a plasmid encoding the wild-type p53 gene to MDR osteosarcoma cell lines, which have different p53 statuses, U-2OSR2 with wild-type p53 (Wt-p53) and KHOSR2 with mutant p53 (Mt-p53), and determined the effect of p53 overexpression on chemosensitivities.

Results: Both of the U-2OSR2 and KHOSR2 cell lines displayed similar trends in p53-induced drug sensitivities. However, it seems that the impact of p53 overexpression is different based on the differential intrinsic p53 status in these cell lines. In the KHOSR2 cell line (Mt-p53), overexpression of p53 up-regulates the expression of pro-apoptotic protein p21 and Bax, while in the U-2OSR2 cell line (Wt-p53), overexpression of p53 down-regulates IGF-1r expression significantly.

Conclusions: These results demonstrated that transfection of wild-type p53 increases chemosensitivity either through inhibiting IGF-1r or through increasing the expression of pro-apoptotic proteins p21 and Bax in human MDR osteosarcoma cell lines.

Keywords: Apoptosis; MDR; Osteosarcoma; p53.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / genetics
  • Cell Line, Tumor
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Drug Resistance, Multiple / genetics*
  • Drug Resistance, Neoplasm / genetics*
  • Gene Expression Profiling
  • Gene Expression Regulation
  • Genes, p53 / genetics*
  • Humans
  • Mutation
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / genetics
  • Pharmacogenetics
  • Receptor, IGF Type 1
  • Receptors, Somatomedin / genetics
  • bcl-2-Associated X Protein / genetics

Substances

  • Antineoplastic Agents
  • Cyclin-Dependent Kinase Inhibitor p21
  • IGF1R protein, human
  • Receptors, Somatomedin
  • bcl-2-Associated X Protein
  • Receptor, IGF Type 1